Integra Lifesciences Holdings (IART) Accumulated Depreciation & Amortization (2010 - 2025)

Integra Lifesciences Holdings has disclosed Accumulated Depreciation & Amortization across 16 years of filings, most recently posting $444.0 million for Q4 2025.

• Accumulated Depreciation & Amortization for Q4 2025 came in at $444.0 million, up 11.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $444.0 million (up 11.85% YoY), and the FY2025 annual result was $444.0 million, up 11.85% from the prior year.
• Accumulated Depreciation & Amortization came in at $444.0 million for Q4 2025 at Integra Lifesciences Holdings, up from $396.9 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $444.0 million in Q4 2025 to a low of $314.9 million in Q4 2021.
• The 5-year median for Accumulated Depreciation & Amortization is $367.4 million (2023), against an average of $370.6 million.
• Across the five-year window, Accumulated Depreciation & Amortization gained 4.72% in 2022 and increased 11.85% in 2025, its largest moves.
• Integra Lifesciences Holdings' Accumulated Depreciation & Amortization stood at $314.9 million in 2021, then gained by 4.72% to $329.7 million in 2022, then increased by 11.44% to $367.4 million in 2023, then gained by 8.02% to $396.9 million in 2024, then rose by 11.85% to $444.0 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $444.0 million (Q4 2025), $396.9 million (Q4 2024), and $367.4 million (Q4 2023), per Business Quant data.